Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : Adc therapeutics sa save search
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
ADCT | $4.97 6.2% 4.43% 380K
|
Health Technology
|
| O: 0.82%
H: 0.25%
C: -4.96%
phase 2 biopharma china trial t-cell
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
Published: 2021-06-11 (Crawled : 12:43) - fda.gov
ADCT | $4.97 6.2% 4.43% 380K
|
Health Technology
|
| O: -0.18%
H: 2.19%
C: 0.14%
fda granted approval grant t-cell
ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
ADCT | $4.97 6.2% 4.43% 380K
|
Health Technology
|
| O: -0.67%
H: 2.95%
C: -1.79%
cancer t-cell
ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-04-23 (Crawled : 23:00) - biospace.com/
ADCT | $4.97 6.2% 4.43% 380K
|
Health Technology
|
| O: 1.84%
H: 8.65%
C: -6.44%
fda fda approval approval t-cell
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
Published: 2021-04-23 (Crawled : 18:42) - fda.gov
ADCT | $4.97 6.2% 4.43% 380K
|
Health Technology
| Email alert
Add to watchlist
fda approval granted grant t-cell
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.